Exploristics
Exploristics is a Belfast-based biostatistics and data science company that provides cloud-based clinical trial simulation software (KerusCloud) and related services to pharmaceutical and biotech sponsors, now operating as a subsidiary of MMS Holdings.
- Company typePrivate
- Founded2009
- HeadquartersBelfast, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Exploristics does
Exploristics is a Northern Ireland-based biostatistics and data science company founded in 2009 and headquartered in Belfast. It serves pharmaceutical and biotech companies requiring clinical trial design, biostatistics, and study simulation services. The company built its offering around a single core product, KerusCloud, which is described as a cloud-based study simulation platform that applies predictive modeling to forecast trial outcomes and optimize study design before real-world execution. The platform is positioned to de-risk clinical development programs and reduce time and cost for drug sponsors, with use cases spanning protocol design optimization, virtual study simulation, and downstream data analysis.
The business model is project-based professional services delivered through direct enterprise sales to pharma and biotech clients, with pricing quoted per engagement rather than published. Marketing and distribution appear to rely on direct enterprise engagement and scientific channels rather than a self-serve or transactional motion. The company operated at a small scale (11-50 employees) with no disclosed funding rounds, patents, awards, or named customer logos in the available input. Geographic operations were anchored in the United Kingdom with broader European reach.
In February 2026, Exploristics was acquired by MMS Holdings, a Michigan-based clinical research organization. The acquisition was explicitly framed as giving MMS access to cloud-based modeling capabilities and a European presence, while making KerusCloud part of MMS's data-focused CRO portfolio. Following the transaction, advised by Osborne Clarke, Exploristics operates as a wholly-owned subsidiary of MMS Holdings, and its independent go-to-market has been absorbed into the parent's CRO infrastructure.
Exploristics firmographics
Firmographics- Name
- Exploristics
- Legal name
- Exploristics Ltd
- Website
- https://exploristics.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Exploristics is a Belfast-based biostatistics and data science company that provides cloud-based clinical trial simulation software (KerusCloud) and related services to pharmaceutical and biotech sponsors, now operating as a subsidiary of MMS Holdings.
- Ownership category
- akta.pro rank
Exploristics industry classification
Industry- Product category
- Clinical Trial Simulation Software
- NAICS
- Other Scientific and Technical Consulting Services (541690), Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)
- akta.pro secondary industries
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
Keywords
Where Exploristics is headquartered
LocationHeadquarters
- HQ city
- Belfast
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Exploristics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: Exploristics generated revenue by providing biostatistics, data science, and clinical trial simulation services to pharmaceutical and biotech companies. As a specialized CRO, the company likely operated on project-based contracts with pharmaceutical clients for study design and data analysis services.
Go-to-market motion1 record
Distribution channels1 record
Exploristics product offering
Product offeringCore offering
Exploristics provides biosimulation software and biostatistics services for designing, analyzing, and reporting clinical trials and real-world studies. Its flagship product, KerusCloud, is a cloud-based study simulation platform that uses predictive modeling to simulate clinical trials virtually before they are conducted, enabling pharmaceutical and biotech companies to de-risk clinical development, reduce development time, and lower costs.
Product overview
Exploristics is a biostatistics and data science company that offers a single unified cloud-based platform called KerusCloud. This flagship study simulation product enables pharmaceutical and biotech companies to model and simulate clinical trials, helping to de-risk development programs and reduce time-to-market. Following its acquisition by MMS Holdings in February 2026, the platform strengthens MMS's data-focused CRO capabilities and expands its European presence.
Differentiator
Problem solved
Functional benefit
Brands
- KerusCloud: Flagship study simulation product of Exploristics designed to de-risk clinical trials and reduce development time and costs. The platform provides cloud-based modeling capabilities for clinical research.
Products and services
- KerusCloud A cloud-based study simulation platform that enables pharmaceutical and biotech companies to model and simulate clinical trials virtually before conducting them, using predictive analytics to forecast trial outcomes and optimize study design. It de-risks drug development, reduces development time, and lowers costs.
Quantifiable outcome
- De-risks clinical trials and reduces development time and costs
Companies that use Exploristics
Customer profileSegments1 record
Ideal customer profiles1 record
Exploristics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature1 record
Exploristics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MMS HoldingscoreMMS Holdings, a Michigan-based clinical research organization, acquired Exploristics in February 2026. This acquisition strengthened MMS's strategic capabilities as a data-focused CRO, expanding its expertise and global reach across Europe through Exploristics' flagship study simulation product KerusCloud. The acquisition provided MMS access to cloud-based modeling capabilities and expanded its presence in the European market.
Scale indicators3 records
Recent moves3 records
Expansion highlights3 records
Exploristics competitors and assessment
Company assessmentDirect peers
- MMS Holdings: Acquirer and now parent company; a Michigan-based clinical research organization with data-focused CRO capabilities. Directly comparable as a CRO serving pharma/biotech, and now operationally integrated with Exploristics.
- Cytel: Specialist biostatistics and clinical trial design CRO with software (e.g., Solara, East) for trial simulation and adaptive design. Closely comparable to Exploristics in offering biostatistics services plus proprietary simulation technology to pharma sponsors.
- Berry Consultants: Statistical consulting firm specializing in Bayesian adaptive clinical trial design and simulation. Directly comparable niche competitor in clinical trial simulation and biostatistics services for pharma/biotech.
- Certara: Biosimulation and modeling & simulation software company serving pharma R&D (e.g., Phoenix WinNonlin, Simcyp). Comparable as a software-led biosimulation provider targeting drug development decision-making.
- Simulations Plus: Provides modeling and simulation software (GastroPlus, MonolixSuite, Lixoft) for pharmaceutical R&D. Directly comparable as a proprietary biosimulation software vendor for clinical and preclinical drug development.
- Phastar: Specialist biostatistics, data science and clinical research services CRO. Comparable peer in providing biostatistics and clinical trial analytics services to pharmaceutical and biotech clients.
Broad incumbents
- Medidata Solutions (Dassault Systèmes): Market-leading clinical trial technology platform (Rave EDC, RTSM, eCOA) acquired by Dassault Systèmes. Comparable as a broad clinical trials informatics provider with overlapping capabilities in trial design and data management.
- ICON plc: Large global CRO with substantial biostatistics and clinical trial design services. Comparable as an incumbent that competes for the same pharma/biostatistics budget pool, with broader scale and service breadth.
- Clario: Clinical trial endpoint technology and services company with eCOA, imaging, and respiratory solutions. Comparable as a clinical trials technology/services vendor serving similar pharma/biotech sponsors.
Others
- Parexel: Large global CRO offering biostatistics, clinical trial design, and full-service drug development. Comparable as a broad incumbent CRO whose biostatistics and trial design practices overlap with Exploristics' core offering.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Exploristics social profiles
Digital presenceExploristics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Exploristics leadership team
Management profileNumber of profiles
Profiles1 record
Exploristics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Exploristics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Exploristics
What does Exploristics do?
Exploristics provides biosimulation software and biostatistics services for designing, analyzing, and reporting clinical trials and real-world studies. Its flagship product, KerusCloud, is a cloud-based study simulation platform that uses predictive modeling to simulate clinical trials virtually before they are conducted, enabling pharmaceutical and biotech companies to de-risk clinical development, reduce development time, and lower costs.
Is Exploristics a public or private company?
Exploristics is a private company. It is classified as corporate owned and is currently acquired.
When was Exploristics founded?
Exploristics was founded in 2009. It employs 11 to 50 people.
Where is Exploristics based?
Exploristics is headquartered in Belfast, United Kingdom, in the Europe region.
How does Exploristics make money?
One revenue line is on record: clinical Research Services.
Who are Exploristics's main competitors?
Direct peers on record are MMS Holdings, Cytel, Berry Consultants, Certara, Simulations Plus and Phastar. Broad incumbents are Medidata Solutions (Dassault Systèmes), ICON plc and Clario. Parexel is listed as an others.
Does Exploristics have an API?
No public API is recorded for Exploristics.
What industry is Exploristics in?
Exploristics's product category is Clinical Trial Simulation Software. Its primary akta.pro industry code is HLACAOAO, Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 541690 and its SIC code is 8731.